Mechanism of action
Isotretinoin reduces sebaceous gland size and sebum production by approximately 90%, which is the most significant mechanism for its anti-acne effect. It normalizes follicular keratinization, reducing the formation of comedones by decreasing the cohesiveness of follicular epithelial cells. The drug also has anti-inflammatory properties and indirectly reduces Cutibacterium acnes (formerly Propionibacterium acnes) colonization by altering the follicular microenvironment.
Isotretinoin binds to nuclear retinoid receptors, particularly retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell proliferation, differentiation, and apoptosis of sebocytes. These effects are dose-dependent and cumulative, with sustained remission often achieved after reaching a cumulative dose threshold.
- Isotretinoin is teratogenic (Pregnancy Category X); causes craniofacial, cardiac, CNS, and thymic malformations.
- iPLEDGE program requires two forms of contraception, monthly pregnancy tests, and monthly dispensing limits.
- Cheilitis (dry, cracked lips) occurs in nearly all patients — most common adverse effect.
- Avoid concurrent tetracyclines due to increased risk of pseudotumor cerebri (benign intracranial hypertension).
- Hypertriglyceridemia occurs in 25-50% of patients; severe elevation (>800 mg/dL) increases pancreatitis risk.
- Cumulative dose of 120-150 mg/kg correlates with sustained remission and lower relapse rates.
- Absorption is increased twofold when taken with high-fat meals; counsel patients accordingly.
- Avoid dermabrasion, waxing, and laser procedures during and for 6-12 months after treatment due to scarring risk.
Indications
The primary indication for isotretinoin is severe recalcitrant nodular acne vulgaris that has not responded adequately to conventional therapy, including systemic antibiotics. Severe nodular acne is defined as the presence of many nodules (large, painful lesions) that may lead to scarring.
Other dermatologic uses include:
- Moderate acne that is recalcitrant to treatment or causing significant psychological distress or scarring
- Acne conglobata
- Gram-negative folliculitis
- Rosacea (severe, refractory cases)
- Hidradenitis suppurativa (off-label)
- Certain disorders of keratinization (e.g., severe ichthyosis, lamellar ichthyosis)
- Chemoprevention of skin cancer in high-risk patients (e.g., xeroderma pigmentosum)
Treatment duration is typically 15 to 20 weeks, with dosing adjusted to achieve a cumulative dose that correlates with sustained remission.
Pharmacokinetics
Absorption: Isotretinoin is absorbed from the gastrointestinal tract, with bioavailability significantly enhanced (up to twofold) when taken with a high-fat meal. Peak plasma concentrations are reached in 2 to 4 hours.
Distribution: The drug is highly lipophilic and distributes into various tissues. It is approximately 99.9% protein-bound, primarily to albumin. Isotretinoin does not accumulate in tissues to a significant extent despite its lipophilic nature.
Metabolism: Hepatic metabolism occurs via CYP2C8, CYP2C9, CYP2B6, and CYP3A4, producing several metabolites including 4-oxo-isotretinoin (the major metabolite), tretinoin (all-trans-retinoic acid), and 4-oxo-tretinoin. Some metabolites possess biologic activity.
Elimination: The elimination half-life of isotretinoin is 10 to 20 hours, while the major metabolite 4-oxo-isotretinoin has a half-life of 20 to 50 hours. Excretion occurs via both renal and fecal routes in approximately equal proportions. Steady state is reached in about 5 to 7 days.
Adverse effects
Teratogenicity
Teratogenicity is the most serious adverse effect. Isotretinoin causes severe birth defects including craniofacial, cardiac, thymic, and central nervous system malformations. There is an extremely high risk (25-35%) of major fetal abnormalities if pregnancy occurs during treatment. Spontaneous abortion is also common. This necessitates strict contraception requirements.
Mucocutaneous effects
These are the most common adverse effects, occurring in the majority of patients:
- Cheilitis (dry, cracked lips) — nearly universal
- Xerosis (dry skin), desquamation
- Dry nasal mucosa, epistaxis
- Conjunctivitis, dry eyes (may be problematic for contact lens wearers)
- Photosensitivity
- Skin fragility, impaired wound healing
- Pruritus
Musculoskeletal effects
- Arthralgia and myalgia (common, especially in athletes)
- Premature epiphyseal closure (pediatric concern with prolonged use)
- Hyperostosis, calcification of tendons and ligaments (with very prolonged use)
- Elevated creatine kinase
Laboratory abnormalities
- Hypertriglyceridemia (25-50% of patients) — may be severe, risk of pancreatitis if >800 mg/dL
- Hypercholesterolemia
- Transaminitis (elevated AST, ALT) — usually mild, dose-related
- Decreased HDL cholesterol
Neuropsychiatric effects
- Headache
- Pseudotumor cerebri (benign intracranial hypertension) — especially when combined with tetracyclines
- Controversial association with depression and suicidal ideation (causal relationship not definitively established, but monitoring recommended)
Ophthalmologic effects
- Decreased night vision (impaired dark adaptation)
- Corneal opacities
- Keratitis
Other effects
- Inflammatory bowel disease (controversial association)
- Pancreatitis
- Hearing impairment (rare)
Contraindications and warnings
Absolute contraindications
- Pregnancy (Pregnancy Category X)
- Hypersensitivity to isotretinoin, other retinoids, parabens (present in some formulations), or any component
- Breastfeeding (isotretinoin is excreted in breast milk)
Relative contraindications and warnings
- Hyperlipidemia or hypertriglyceridemia — monitor lipid panel; risk of pancreatitis
- Hepatic impairment — may worsen liver function
- History of depression or psychiatric disorders — monitor for mood changes
- Diabetes mellitus — may alter glycemic control
- Concurrent tetracycline use — increased risk of pseudotumor cerebri
- History of inflammatory bowel disease
- Pediatric patients with bone growth concerns
iPLEDGE program (United States)
Isotretinoin is available only through the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program due to teratogenicity. Requirements include:
- Two forms of contraception must be used simultaneously for females of reproductive potential, starting 1 month before treatment, during treatment, and for 1 month after discontinuation
- Two negative pregnancy tests before initiation (one in office)
- Monthly pregnancy tests and counseling
- Monthly refill limits (maximum 30-day supply)
- Prescribers, patients, and pharmacies must all be registered
- Males must also be registered and counseled about the risks
Blood donation is prohibited during treatment and for 1 month after discontinuation due to teratogenicity risk if transfused to a pregnant woman.
Drug interactions
- Tetracyclines (tetracycline, doxycycline, minocycline) — increased risk of pseudotumor cerebri (benign intracranial hypertension); avoid concurrent use
- Vitamin A supplements — additive toxicity (hypervitaminosis A); avoid concurrent use
- Corticosteroids — may increase risk of osteoporosis with prolonged use
- Phenytoin — isotretinoin may decrease phenytoin levels (theoretical, based on protein binding displacement)
- Hormonal contraceptives — progestin-only oral contraceptives ("mini-pills") may have reduced efficacy; combination oral contraceptives are preferred, but two forms of contraception are still required
- Keratolytic agents (topical tretinoin, benzoyl peroxide, salicylic acid, alpha-hydroxy acids) — increased skin irritation; avoid aggressive topical therapy during isotretinoin treatment
- Alcohol — potential additive hepatotoxicity and increased triglycerides
- St. John's Wort — may reduce hormonal contraceptive efficacy
CYP-mediated interactions are generally not clinically significant because isotretinoin is metabolized by multiple CYP enzymes.
Clinical pearls
- A cumulative dose of 120 to 150 mg/kg over the treatment course is associated with higher long-term remission rates and lower relapse rates compared to lower cumulative doses.
- Acne flare may occur in the first few weeks of treatment, particularly in patients with severe inflammatory acne. Concurrent use of oral corticosteroids may be considered to prevent or manage flares.
- Patients should be counseled to take isotretinoin with food (preferably high-fat meals) to optimize absorption and bioavailability.
- Baseline and follow-up laboratory monitoring should include: fasting lipid panel (triglycerides, cholesterol, HDL, LDL), liver function tests (AST, ALT), and pregnancy test (for females of reproductive potential). Monitoring frequency is typically monthly initially, then may be extended if stable.
- Patients should use gentle, non-comedogenic moisturizers and lip balms liberally to manage mucocutaneous dryness. Sunscreen is essential due to photosensitivity.
- Dermabrasion, laser resurfacing, and waxing should be avoided during treatment and for 6 to 12 months after discontinuation due to risk of scarring and impaired wound healing.
- The classic association of isotretinoin with depression and suicide remains controversial. While causality has not been definitively established, patients and families should be counseled about potential mood changes, and patients should be monitored throughout treatment.
- Isotretinoin is sometimes used off-label at lower doses for acne maintenance therapy to prevent relapse, though this is not a standard approach.
- Night vision changes can impact driving ability; warn patients who drive at night.
Practice questions
1. A 19-year-old woman with severe nodular acne returns for a follow-up visit 2 months after starting isotretinoin. She reports significant improvement in her acne but complains of severe dry lips and occasional nosebleeds. Laboratory studies show: triglycerides 450 mg/dL (normal <150), ALT 52 U/L (normal 7-56), and AST 48 U/L (normal 10-40). Pregnancy test is negative. Which of the following is the most appropriate next step in management?
2. A 16-year-old girl with severe cystic acne is started on isotretinoin. Two weeks later, she presents to the emergency department with severe headache, nausea, and blurred vision. On examination, she has bilateral papilledema. Opening pressure on lumbar puncture is markedly elevated, and CSF analysis is otherwise normal. Which of the following medications, if taken concurrently, most likely contributed to this patient's presentation?
3. A 22-year-old woman who completed a 6-month course of isotretinoin for severe acne 2 weeks ago calls her dermatologist requesting permission to donate blood at an upcoming blood drive at her workplace. Her acne has cleared, and she has had no complications from treatment. Her last menstrual period was 1 week ago, and she continues to use two forms of contraception. What should the dermatologist advise?
Frequently asked questions
How does isotretinoin work?
Isotretinoin works by dramatically reducing sebaceous gland size and sebum production by approximately 90%, normalizing follicular keratinization to prevent comedone formation, and exerting anti-inflammatory effects. It binds to nuclear retinoid receptors (RARs and RXRs) to modulate gene transcription affecting sebocyte proliferation, differentiation, and apoptosis. The cumulative effect over a treatment course leads to sustained remission of severe acne in many patients.
What are the side effects of isotretinoin?
The most serious side effect is severe teratogenicity causing major birth defects. The most common side effects are mucocutaneous: cheilitis (dry, cracked lips) in nearly all patients, dry skin, dry eyes, and nosebleeds. Other important adverse effects include hypertriglyceridemia (25-50%), elevated liver enzymes, myalgias and arthralgias, photosensitivity, and potential mood changes. Rare but serious effects include pseudotumor cerebri (especially with tetracyclines) and pancreatitis from severe hypertriglyceridemia.
Is isotretinoin a controlled substance?
No, isotretinoin is not a DEA-scheduled controlled substance. However, it is only available through the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program in the United States due to its severe teratogenicity. This program requires registration of prescribers, patients, and pharmacies, mandatory contraception and pregnancy testing for females of reproductive potential, and monthly dispensing limits. While not a controlled substance, access is strictly regulated for safety reasons.
Isotretinoin vs tretinoin — what is the difference?
Isotretinoin (13-cis-retinoic acid) and tretinoin (all-trans-retinoic acid) are both vitamin A derivatives but differ in structure and use. Isotretinoin is used systemically (oral) for severe nodular acne and works by dramatically reducing sebum production. Tretinoin is primarily used topically for acne, photoaging, and hyperpigmentation, though it also has a systemic formulation used in acute promyelocytic leukemia. Both are teratogenic, but isotretinoin requires more stringent monitoring due to systemic exposure and higher teratogenic risk.
Why can't you donate blood on isotretinoin?
You cannot donate blood while taking isotretinoin or for one month after stopping because the drug is teratogenic and remains in the bloodstream. If blood containing isotretinoin were transfused into a pregnant woman, it could cause severe birth defects in the fetus, including craniofacial, cardiac, thymic, and central nervous system malformations. The one-month waiting period after discontinuation ensures the drug and its metabolites are eliminated from the body before blood donation is safe.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: D10AD04WHO ATC/DDD index: D10BA01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.